Related Experiment Video
Updated: Jul 20, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance
Gabriel Rubio1, Isabel Martínez, Guillermo Ponce
1Department of Psychiatry, Complutense University, Madrid, Spain. garuva@inicia.es
Objective:
This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse.
Method:
A total of 115 subjects with schizophrenia and substance use disorders were enrolled for an open, randomized, controlled, 6-month follow-up study. Fifty-seven subjects were selected for treatment with long-acting injectable risperidone, while another 58 were treated with zuclopenthixol-depot.
Results:
Long-acting risperidone patients presented fewer positive urine tests (8.67 compared with 10.36, P = 0.005), showed improved scores on the Positive and Negative Syndrome Scale, and showed better compliance with the Substance Abuse Management program. The use of long-acting risperidone and less severe dependence explained the outcome at the end of the follow-up.
Conclusions:
Long-acting injectable risperidone was more effective than zuclopenthixol-depot in improving substance abuse and schizophrenia symptoms in subjects with dual diagnosis.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections